National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Empagliflozin (Jardiance®). HTA ID: 22068

Empagliflozin (Jardiance®) is indicated in adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40%.

 

NCPE Assessment Process Complete
Rapid review commissioned 02/11/2022
Rapid review completed 02/12/2022
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that empagliflozin for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40% be considered for reimbursement*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.